CURE vs DRUG - Compare ETFs side by side

At a glance

Comparing CURE and DRUG. CURE has the lower management fee at 0.45% a year, CURE has the higher 5 years return at 4.3% a year, and DRUG offers the higher at 4%.

Lower fee

CURE 0.45% p.a.

Higher 5 years return

CURE 4.3% p.a.

Higher yield

DRUG 4%

Higher risk-adjusted

CURE Sharpe 0.16 (5y)

Lower volatility

DRUG 13.2% (5y)

Larger fund

DRUG $172m

Side-by-side comparison

Metric	CURE Global X S&P Biotech ETF	DRUG BetaShares Global Healthcare ETF - Currency Hedged
Snapshot
Provider	Global X	BetaShares
Tracks index	S&P Biotechnology Select Industry Index	Nasdaq Global ex-Australia Healthcare Hedged AUD Index
Categories	US, Thematic	Intl, Thematic
Listed since	2021 (5 yrs)	—
Fund size (AUM)	$46m	$172m
Cost & income
Management fee	0.45%	0.57%
Dividend yield	0%	4%
Franking	0%	0%
Turnover	35%	—
Tax drag	0.84%	1.28%
Returns	Tax bracket - adjusts tax drag & net returns
1-year return	57.4% net	20.8% net
3-year return	18.5% net	5.7% net
5-year return	4.3% net	4.2% net
10-year return	—	—
Risk
Volatility (3y)	25.5%	12.6%
Volatility (5y)	24.9%	13.2%
Volatility (10y)	—	—
Sharpe ratio (3y)	0.63	0.18
Sharpe ratio (5y)	0.16	0.13
Sharpe ratio (10y)	—	—
Bid/ask spread	—	—

marks the strongest fund in each row. “net” shows the after-tax return at your selected bracket. “—” means we don’t have that data point yet.

Each fund at a glance

CURE Global X S&P Biotech ETF

Top-2% returns over 1 year (7th of 308 ETFs we track).

Cheaper alternatives exist: IXJ and IXI.

Full CURE analysis →

DRUG BetaShares Global Healthcare ETF - Currency Hedged

Top-14% returns over 1 year (43rd of 308 ETFs we track).
Pays a useful 4% income yield.

Has lagged most peers over 3 years (169th of 226).

Full DRUG analysis →

Frequently Asked Questions

What's the difference between CURE vs DRUG?

CURE and DRUG are 2 Australian-listed ETFs we compare side by side. CURE carries the lower management fee (0.45%). Over 5 years, CURE has delivered the higher total return (4.3% a year). The table above breaks down fees, returns, income and risk for each.

Which has the lower fees - CURE vs DRUG?

CURE has the lower management fee at 0.45% a year, versus DRUG 0.57%.

Which has performed higher - CURE vs DRUG?

Over the past 5 years, CURE has delivered the higher total return at 4.3% a year. Past performance is not a reliable indicator of future returns.

Which pays the higher dividend yield?

DRUG pays the higher at 4%. Remember distributions are taxed each year at your marginal rate.

Which is the larger and most liquid?

DRUG is the larger fund by assets ($172m). Larger funds are typically more liquid and trade on tighter spreads.

Related comparisons

CURE vs IXJ CURE vs IXI CURE vs HLTH DRUG vs IXJ DRUG vs HLTH

← Back to all ETFs

General information only, generated from each fund's published data — not personal financial advice. Past performance is not a reliable indicator of future returns. Consider your own circumstances or seek licensed advice before investing.